Companies: 10,795·Total market cap: $144.5T
ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc.

ORICNASDAQHealthcare● Active
$7.53
+$0.03(+0.40%)
Market Cap$779487242
P/E Ratio
52W High$14.93
52W Low$7.23

ORIC Pharmaceuticals, Inc. (ORIC) Revenue

Annual & quarterly revenue history · segment & region breakdown

ORIC · revenue · updated Jun 8, 2026

Core revenue metrics

ORIC Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY2025 $0.00B
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
122 employees
FY2025
$0.00B
FY2024
$0.00B
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · ORIC Pharmaceuticals, Inc. SEC filings · GAAPUpdated: 2026-06-08

Revenue trend

20252017 · Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
2025-12-31$0.00B+$0.00B
2024-12-31$0.00B+$0.00B
2023-12-31$0.00B+$0.00B
2022-12-31$0.00B+$0.00B
2021-12-31$0.00B+$0.00B
2020-12-31$0.00B+$0.00B
2019-12-31$0.00B+$0.00B
2018-12-31$0.00B+$0.00B
2017-12-31$0.00B
ORIC revenue by year · ORIC revenue history · ORIC annual revenue data

Compare revenue vs peers

Biotechnology

Compare ORIC revenue against listed peers. Click any row to open that company's revenue tab.

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income ORIC Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

ORIC Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from ORIC Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

ORIC revenue · 4 questions

ORIC's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.

ORIC revenueORIC annual revenuewhat is ORIC revenueORIC TTM revenue

Source: FMP · ORIC Pharmaceuticals, Inc. SEC filings · GAAP · ORIC Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026